Please use this identifier to cite or link to this item: http://hdl.handle.net/123456789/693
Full metadata record
DC FieldValueLanguage
dc.contributor.authorPanda, Amulya K; Talwar, GP; Nand, Kripa N; Gupta, Jagdish C; Jain, Swatantra K-
dc.date.accessioned2016-03-22T10:40:48Z-
dc.date.available2016-03-22T10:40:48Z-
dc.date.issued2015-10-
dc.identifier.urihttp://hdl.handle.net/123456789/693-
dc.description.abstractPROBLEM: Necessity to elicit antibody response above the protective threshold titres by sexually active women immunized to prevent pregnancy. METHOD OF STUDY: Recombinant hCGβ-LTB vaccine expressed as both DNA and protein. Balb C mice employed for testing immunogenicity. RESULTS: Necessity to give three primary injections of the vaccine to elicit proper antibody response. Immunization twice with DNA form of the vaccine at fortnightly interval followed by the protein elicits a distinctly higher antibody response than proteinic vaccine alone. Antibodies generated are bio-effective against hCG. CONCLUSION: Immunization with the DNA form of the recombinant hCGβ-LTB vaccine twice at fortnightly interval followed by the proteinic form of the vaccine induces distinctly higher antibody response.en_US
dc.publisherJohn Wiley & Sons Ltd.en_US
dc.titlePriming with DNA Enhances Considerably the Immunogenicity of hCG b-LTB Vaccineen_US
dc.keywordDNA Vaccine, human chorionic gonadotropin (hCG), Mycobacterium indicus pranii (MiP)en_US
dc.journalAmerican Journal of Reproductive Immunologyen_US
dc.volumeno74en_US
dc.issueno4en_US
dc.pages302-308en_US
Appears in Collections:Product Development Cell Unit- II, Publications

Files in This Item:
File Description SizeFormat 
Nand_et_al-2015-American_Journal_of_Reproductive_Immunology.pdfResearch article323.6 kBAdobe PDFView/Open    Request a copy


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.